These findings extend those recently reported in NPC, hepatocellular carcinoma, which are virus-associated cancers and has also been considered as “immunogenic.” Our studies support a rationale for administering anti-PD-1 and anti-PD-L1 therapies to the EBV infected pulmonary LELC population. This evidence concerns the gene CD274 and hepatocellular carcinoma.